Viking Therapeutics Inc (NAS:VKTX)
$ 58.88 2.65 (4.71%) Market Cap: 6.49 Bil Enterprise Value: 5.24 Bil PE Ratio: 0 PB Ratio: 6.95 GF Score: 38/100

Viking Therapeutics Inc Top-Line Results from Phase 2b VOYAGE Study of VK2809 Call Transcript

May 16, 2023 / 12:00PM GMT
Release Date Price: $24.65 (+12.07%)
Operator

Good morning, everyone, and welcome to the Viking Therapeutics Phase IIb VOYAGE study top-line data conference call. (Operator Instructions).

As a reminder, this conference call is being recorded today, May 16, 2023. I would now like to turn the floor over to Viking's Manager of Investor Relations, Stephanie Diaz. Please go ahead, Stephanie.

Stephanie C. Diaz
Vida Strategic Partners Inc. - President & CEO

Hello, and thank you all for participating in today's call. Joining me today is Brian Lian, Viking's President and CEO; Marianne Mancini, the company's Chief Operating Officer; and Greg Zante, Viking's Chief Financial Officer.

Before we begin, I'd like to caution that comments made during this conference call today, May 16, 2023, will contain forward-looking statements under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Viking's expectations regarding its development activities, timelines and milestones.

Forward-looking statements are subject to risks and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot